Eliem Therapeutics Inc (NASDAQ: ELYM)’s stock price has gone rise by 21.04 in comparison to its previous close of 8.39, however, the company has experienced a 155.15% increase in its stock price over the last five trading days. Zacks Investment Research reported 2023-07-21 that Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
Is It Worth Investing in Eliem Therapeutics Inc (NASDAQ: ELYM) Right Now?
The stock has a 36-month beta value of -0.35. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ELYM is 18.44M, and at present, short sellers hold a 3.26% of that float. On May 06, 2024, the average trading volume of ELYM was 852.40K shares.
ELYM’s Market Performance
ELYM’s stock has seen a 155.15% increase for the week, with a 263.98% rise in the past month and a 296.68% gain in the past quarter. The volatility ratio for the week is 34.50%, and the volatility levels for the past 30 days are at 17.52% for Eliem Therapeutics Inc The simple moving average for the past 20 days is 130.72% for ELYM’s stock, with a 255.27% simple moving average for the past 200 days.
ELYM Trading at 198.09% from the 50-Day Moving Average
After a stumble in the market that brought ELYM to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 16.06% of gains for the given period.
Volatility was left at 17.52%, however, over the last 30 days, the volatility rate increased by 34.50%, as shares surge +290.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +274.67% upper at present.
During the last 5 trading sessions, ELYM rose by +155.15%, which changed the moving average for the period of 200-days by +240.77% in comparison to the 20-day moving average, which settled at $4.78. In addition, Eliem Therapeutics Inc saw 276.11% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ELYM
The total capital return value is set at -0.37. Equity return is now at value -29.72, with -28.61 for asset returns.
Based on Eliem Therapeutics Inc (ELYM), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -59.02.
Currently, EBITDA for the company is -40.27 million with net debt to EBITDA at 2.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 38.92.
Conclusion
To sum up, Eliem Therapeutics Inc (ELYM) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
